DOCSLIB.ORG

Supplemental Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ARTICLE Supplemental Information PEDIATRICS Volume 146, Number 1, July 2020 1 SUPPLEMENTAL TABLE 3 Diagnostic and Procedure Codes Defining Cohort Characteristics Variable Diagnostic or Procedure Codes Deliveries CPT codes: 01960, 01961, 01962, 01963, 01967, 01968, 01969, 59050, 59051, 59400, 59409, 59410, 59412, 59414, 59430, 59510, 59514, 59515, 59525, 59610, 59612, 59614, 59618, 59620, 59622, 99436, and 99440; ICD-9 procedure codes: 72, 72.0, 72.1, 72.2, 72.21, 72.29, 72.3, 72.31, 72.39, 72.4, 72.5, 72.51, 72.52, 72.53, 72.54, 72.6, 72.7, 72.71, 72.79, 72.8, 72.9, 73, 73.0, 73.01, 73.09, 73.1, 73.2, 73.21, 73.22, 73.3, 73.4, 73.5, 73.51, 73.59, 73.6, 73.8, 73.9, 73.91, 73.92, 73.93, 73.94, 73.99, 74, 74.0, 74.1, 74.2, 74.4, 74.9, 74.91, 74.99, and 75.4; ICD-10 procedure codes: 10D07Z3, 10D07Z4, 10D07Z5, 10D07Z6, 10D07Z7, 10S07ZZ, 10900ZC, 10903ZC, 10904ZC, 10907ZC, 10908ZC, 0U7C7ZZ, 10J07ZZ, 3E0P7GC, 10E0XZZ, 0W8NXZZ, 10907ZA, 10908ZA, 10S0XZZ, 10D07Z8, 10D00Z0, 10D00Z1, 10D00Z2, 10A00ZZ, 10A03ZZ, 10A04ZZ, 10D17ZZ, and 10D18ZZ; ICD-9 diagnosis codes: V27.x and V30.xx–V39.xx; ICD-10 diagnosis codes: Z37–Z38 Depression ICD-9 diagnosis codes: 296.2x, 296.3x, 296.90x, 298.0x, 309.0x, 309.1x, and 311.x; ICD-10 diagnosis codes: F32.x–F34.x, F38.x, and F39.x, Anxiety ICD-9 diagnosis codes: 300.0.x and 300.4x; ICD-10 diagnosis codes: F40–F48 Other mental health ICD-9 diagnosis codes: 295.x, 296.0x–296.1x, 296.4x–296.8x, 297.xx, 298.1x–298.9x, 300.1x–300.3x, 300.5x–300.9x, 301.x, 308.x, 309.2x–309.9x, 312.x, and 648.4x; ICD-10 diagnosis codes: F20.x–F29.x, F30.x–F31.x, F40.x, F42.x–F45.x, F48.x, F60.x–F61.x, F91.x–F92.x, O99.34x, O90.6x, and F53.x Pain disorder ICD-9 diagnosis codes: 338.xx, 346.xx, 780.96, 729.1x, 531.x–534.x, 555.x, 556.x, 564.1x, 710.0x, and 714.x; ICD-10 diagnosis codes: G43x, G89.x, R52.x, M79.x, M05.x, M06.x, M08.x, M32.1x, M32.8x, M32.9x, K25.x–K28.x, K50.x–K51.x, and K58.x Sleep disorder ICD-9 diagnosis codes: 307.41, 307.42, 307.45, 307.49, and 780.50–780.52; ICD-10 diagnosis codes: F51.0x, F51.8x, F51.9x, G47.0x, and G47.2x Antidepressants SSRIs: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline; SNRIs: levomilnacipran, venlafaxine, duloxetine, and desvenlafaxine; bupropion; other: vilazodone, vortioxetine, reboxetine, mirtazapine, nefazodone, selegiline, mianserin, reboxetine, trazodone, amoxapine, maprotiline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, amytriptyline, clomipramine, desipramine, dothiepin, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine Benzodiazepines Alprazolam, bromazepam, chlordiazepoxide, clonazepam, clorazepate, clobazam, diazepam, estazolam, flurazepam, halazepam, lorazepam, nitrazepam, oxazepam, prazepam, temazepam, and triazolam Antipsychotics Acetophenazine, acetylpromazine maleate, aripiprazole, butaperazine maleate, chlorproethazine, chlorpromazine, chlorprothixene, clothiapine, clozapine, cyamemazine, dixyrazine, droperidol, fluanisone, flupenthixol or flupentixol, fenazine, fluphenazine decanoate, fluphenazine enanthate, asenapine, fluspirilene, haloperidol, loxapine succinate, melperone, mepazine, mesoridazine besylate, methotrimeprazine, metofenazate difumarate, metopimazine, molindone, moperone, olanzapine, paliperidone, perazine, perphenazine, perphenazine enanthate, cariprazine, pimozide, pipamperone, piperacetazine, prochlorperazine, prochlorperazine dimaleate, prochlorperazine edisylate, prochlorperazine maleate, prochlorperazine mesylate, promazine, propericiazine, propiomazine, quetiapine, risperidone, sulpiride, tetrabenazine, thiethylperazine, thiethylperazine maleate, thiopropazate, thioproperazine, thioridazine, thiothixene, tiapride, trifluoperazine, triflupromazine, iloperidone, veralipride, ziprasidone, zuclopenthixol, zotepine, and pimavanserin Hypertension ICD-9 diagnosis codes: 401.x–405.x; ICD-10 diagnosis codes: I10.x–I15.x Major cardiac malformations At least 2 of the following ICD-9 diagnosis codes: 745, 745.0x, 745.1x, 745.10, 745.11, 745.12, 745.19, 745.2x, 745.3x, 745.6x, 745.60, 745.61, 745.69, 745.7x, 745.8x, 745.9x, 746, 746.00, 746.1x, 746.2x, 746.3x, 746.5x, 746.7x, 746.8, 746.80, 746.82, 746.84, 746.85, 746.86, 746.87, 746.89, 747, 747.1x, 747.10, 747.11, 747.2x, 747.20, 747.21, 747.22, 747.29, 747.4x, 747.40, 747.41, 747.42, 747.49, 747.83, 746.9x, 746.01, 746.09, 746.83, 747.3x and no preterm delivery codes in first 60 d after delivery, 746.02 and no preterm delivery codes in first 60 d after delivery, and 745.4x; and ICD-10 diagnosis codes: Q20–Q28. At least 1 of the previous codes plus 1 of the following ICD-9 procedure codes: 35.x, 36.x, 37.x (except 37.94), 38.x (except 38.18, 38.91, 38.92, 38.93, 38.94, 38.95, 38.98, 2 ARTICLE SUPPLEMENTAL TABLE 3 Continued Variable Diagnostic or Procedure Codes and 38.99), 39.x (except 39.27, 39.50, 39.95, and 39.98); and CPT codes: 00560, 00561, 00563, 33300–35190, 92992, 92993, 93530, 93531, 93532, and 93533 Newborn respiratory distress ICD-9 diagnosis codes: 769, 770.6, and 770.8; ICD-10 diagnosis code: P22.0 Preterm delivery ICD-9 diagnosis codes: 644.2x, 765.0x, 765.1x, and 765.2; ICD-10 diagnosis codes: P07.2x, P07.3x (from maternal records) Exclusions for known teratogens Chromosomal anomaly: ICD-9 diagnosis codes: 758.x, 759.81, 759.826, and 759.83; ICD-10 diagnosis codes: Q90x–Q99x. Known human teratogen in first 12 wk gestation: acetretin, aminopterin, carbamazepine, isotretinoin, lanalomide, lithium, misoprostol, methotrexate, mycophenolate, thalidomide, topiramate, valporic acid, warafarin SUPPLEMENTAL TABLE 4 Cell Sizes and Unadjusted Effect Estimates for 12-Week Trajectory Assignments and the Risk of Major Malformations na Major % Major Crude RR (95% CI) Malformations Malformations Low use with reduction (A) 6780 99 1.46 Reference Low sustained use (B) 3532 62 1.76 1.20 (0.88–1.65) Moderate use with reduction (C) 1866 34 1.82 1.25 (0.85–1.84) Moderate sustained use (D) 2202 52 2.36 1.61 (1.16–2.25) High sustained use (E) 525 13 2.48 1.70 (0.96–3.00) Depression and no antidepressant use 4906 93 1.90 Reference Low use with reduction (A) 6780 99 1.46 0.77 (0.58–1.02) Low sustained use (B) 3532 62 1.76 0.93 (0.67–1.27) Moderate use with reduction (C) 1866 34 1.82 0.96 (0.65–1.42) Moderate sustained use (D) 2202 52 2.36 1.25 (0.89–1.74) High sustained use (E) 525 13 2.48 1.31 (0.76–2.32) Anxiety and no antidepressant use 9362 191 2.04 Reference Low use with reduction (A) 6780 99 1.46 0.72 (0.56–0.91) Low sustained use (B) 3532 62 1.76 0.86 (0.65–1.14) Moderate use with reduction (C) 1866 34 1.82 0.89 (0.62–1.28) Moderate sustained use (D) 2202 52 2.36 1.16 (0.86–1.57) High sustained use (E) 525 13 2.48 1.21 (0.70–2.11) a A total of 136 were excluded because of a teratogen or chromosomal anomaly in the primary model, 179 were excluded in the depression reference model, and 180 were excluded in the anxiety reference model. SUPPLEMENTAL TABLE 5 Cell Sizes and Unadjusted Effect Estimates for 35-Week Trajectory Assignments and the Risk of Preterm Birth n Preterm % Preterm Crude RR (95% CI) Birth Birth Low use with reduction (A) 7622 769 10.09 Reference Low sustained use (B) 3170 367 11.58 1.15 (1.02–1.29) Moderate use with reduction (C) 1907 191 10.02 0.99 (0.85–1.15) Moderate sustained use (D) 1918 287 14.96 1.48 (1.31–1.68) High sustained use (E) 424 102 24.06 2.39 (1.99–2.86) Depression and no antidepressant use 4949 576 11.64 Reference Low use with reduction (A) 7622 769 10.09 0.86 (0.77–0.95) Low sustained use (B) 3170 367 11.58 0.98 (0.86–1.11) Moderate use with reduction (C) 1907 191 10.02 0.85 (0.73–0.99) Moderate sustained use (D) 1918 287 14.96 1.27 (1.11–1.45) High sustained use (E) 424 102 24.06 2.04 (1.70–2.46) Anxiety and no antidepressant use 9406 1031 10.96 Reference Low use with reduction (A) 7622 769 10.09 0.91 (0.83–0.99) Low sustained use (B) 3170 367 11.58 1.04 (0.93–1.17) Moderate use with reduction (C) 1907 191 10.02 0.91 (0.78–1.05) Moderate sustained use (D) 1918 287 14.96 1.35 (1.19–1.52) High sustained use (E) 424 102 24.06 2.18 (1.82–2.60) PEDIATRICS Volume 146, Number 1, July 2020 3 SUPPLEMENTAL TABLE 6 Cell Sizes and Unadjusted Effect Estimates for 35-Week Trajectory Assignments and the Risk of Neonatal Respiratory Distress n Respiratory % Respiratory Crude RR (95% CI) Distress Distress Low use with reduction (A) 7622 564 7.40 Reference Low sustained use (B) 3170 331 10.44 1.41 (1.24–1.61) Moderate use with reduction (C) 1907 185 9.70 1.31 (1.12–1.54) Moderate sustained use (D) 1918 256 13.35 1.81 (1.57–2.08) High sustained use (E) 424 86 20.28 2.74 (2.24–3.35) Depression and no antidepressant use 4949 360 7.27 Reference Low use with reduction (A) 7622 564 7.40 1.02 (0.90–1.15) Low sustained use (B) 3170 331 10.44 1.43 (1.24–1.65) Moderate use with reduction (C) 1907 185 9.70 1.33 (1.13–1.58) Moderate sustained use (D) 1918 256 13.35 1.84 (1.58–2.14) High sustained use (E) 424 86 20.28 2.78 (2.25–3.44) Anxiety and no antidepressant use 9406 715 7.60 Reference Low use with reduction (A) 7622 564 7.40 0.97 (0.87–1.08) Low sustained use (B) 3170 331 10.44 1.37 (1.21–1.55) Moderate use with reduction (C) 1907 185 9.70 1.28 (1.09–1.49) Moderate sustained use (D) 1918 256 13.35 1.75 (1.54–2.01) High sustained use (E) 424 86 20.28 2.66 (2.18–3.25) SUPPLEMENTAL TABLE 7 Effect Estimates for Trajectory Groups and the Risk of Adverse Perinatal Outcomes, Restricting to Women With SSRI Antidepressants Only na No.
Recommended publications
  • The SULPYCO Method Using Sulpiride Integrated with an Atypical Adjuvant Therapy for Treating Depressive Syndrome: an Observational Study Amgad M

    The SULPYCO Method Using Sulpiride Integrated with an Atypical Adjuvant Therapy for Treating Depressive Syndrome: an Observational Study Amgad M

    oepidem ac io m lo r g a y Rabie, Adv Pharmacoepidem Drug Safety 2013, 2:1 h & P Advances in Pharmacoepidemiology & D n i DOI: 10.4172/2167-1052.1000126 r u s g e c ISSN: 2167-1052 S n a a f v e t d y A Drug Safety Research Article Open Access The SULPYCO Method Using Sulpiride Integrated with an Atypical Adjuvant Therapy for Treating Depressive Syndrome: An Observational Study Amgad M. Rabie* Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, Dakahlia Governorate, Egypt Abstract In this observational study, we studied the effects of a new drug combination on depression. Patients were analyzed before and after antidepressant treatment using the Hamilton rating scale for depression (HAMD). One group of patients was treated with the new integrated medicine consisting of two separate subcutaneous injections of a low dose (20 mg) of sulpiride and a 2.2 ml complex homeopathic solution based on the Krebs cycle elements; each injection was administered once daily. Another group of patients was treated with conventional therapy of 20 mg sulpiride only. The third group was treated with only the homeopathic solution. The differences in the HAMD scores were evaluated before and after 3 months of treatment in these three groups of patients. The HAMD score showed a statistically significant decrease in the group treated with combined sulpiride and homeopathy. This observation suggests that a low parenteral dose (20 mg) of sulpiride, when administered subcutaneously with a complex homeopathic remedy, may give better therapeutic results for mild and moderate depression than either sulpiride or complex homeopathy alone.
  • Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm

    Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm

    Table S1: Sensitivity, specificity, PPV, NPV, and F1 score of NLP vs. ICD for identification of symptoms for (A) BioMe development cohort; (B) BioMe validation cohort; (C) MIMIC-III; (D) 1 year of notes from patients in BioMe calculated using manual chart review. A) Fatigue Nausea and/or vomiting Anxiety Depression NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.99 (0.93- 0.59 (0.43- <0.00 0.25 (0.12- <0.00 <0.00 0.54 (0.33- Sensitivity 0.99 (0.9 – 1) 0.98 (0.88 -1) 0.3 (0.15-0.5) 0.85 (0.65-96) 0.02 1) 0.73) 1 0.42) 1 1 0.73) 0.57 (0.29- 0.9 (0.68- Specificity 0.89 (0.4-1) 0.75 (0.19-1) 0.68 0.97 (0.77-1) 0.03 0.98 (0.83-1) 0.22 0.81 (0.53-0.9) 0.96 (0.79-1) 0.06 0.82) 0.99) 0.99 (0.92- 0.86 (0.71- 0.94 (0.79- 0.79 (0.59- PPV 0.96 (0.82-1) 0.3 0.95 (0.66-1) 0.02 0.95 (0.66-1) 0.16 0.93 (0.68-1) 0.12 1) 0.95) 0.99) 0.92) 0.13 (0.03- <0.00 0.49 (0.33- <0.00 0.66 (0.48- NPV 0.89 (0.4-1) 0.007 0.94 (0.63-1) 0.34 (0.2-0.51) 0.97 (0.81-1) 0.86 (0.6-0.95) 0.04 0.35) 1 0.65) 1 0.81) <0.00 <0.00 <0.00 F1 Score 0.99 0.83 0.88 0.57 0.95 0.63 0.82 0.79 0.002 1 1 1 Itching Cramp Pain NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.98 (0.86- 0.24 (0.09- <0.00 0.09 (0.01- <0.00 0.52 (0.37- <0.00 Sensitivity 0.98 (0.85-1) 0.99 (0.93-1) 1) 0.45) 1 0.29) 1 0.66) 1 0.89 (0.72- 0.5 (0.37- Specificity 0.96 (0.8-1) 0.98 (0.86-1) 0.68 0.98 (0.88-1) 0.18 0.5 (0-1) 1 0.98) 0.66) 0.88 (0.69- PPV 0.96 (0.8-1) 0.8 (0.54-1) 0.32 0.8 (0.16-1) 0.22 0.99 (0.93-1) 0.98 (0.87-1) NA* 0.97) 0.98 (0.85- 0.57 (0.41- <0.00 0.58 (0.43- <0.00 NPV 0.98 (0.86-1) 0.5 (0-1) 0.02 (0-0.08) NA* 1) 0.72) 1 0.72) 1 <0.00 <0.00 <0.00 F1 Score 0.97 0.56 0.91 0.28 0.99 0.68 1 1 1 *Denotes 95% confidence intervals and P values that could not be calculated due to insufficient cells in 2x2 tables.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • The In¯Uence of Medication on Erectile Function

    The In¯Uence of Medication on Erectile Function

    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
  • List of Union Reference Dates A

    List of Union Reference Dates A

    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis

    The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis

    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
  • Enhancing the Low Oral Bioavailability of Sulpiride Via Fast Orally Disintegrating Tablets: Formulation, Optimization and in Vivo Characterization

    Enhancing the Low Oral Bioavailability of Sulpiride Via Fast Orally Disintegrating Tablets: Formulation, Optimization and in Vivo Characterization

    pharmaceuticals Article Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization Hesham M. Tawfeek 1,* , Yasser A. Hassan 2,3, Mohammed F. Aldawsari 4 and Mohamed H. Fayed 4,5 1 Department of Industrial Pharmacy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt 2 Department of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 35523, Egypt; [email protected] 3 Department of Pharmaceutics, College of Pharmacy, Al-Bayan University, Baghdad 10001, Iraq 4 Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj 11942, Saudi Arabia; [email protected] (M.F.A.); [email protected] (M.H.F.) 5 Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Fayoum University, Fayoum 63514, Egypt * Correspondence: [email protected] Received: 24 October 2020; Accepted: 2 December 2020; Published: 5 December 2020 Abstract: Sulpiride (SUL) is a dopamine D2-receptor antagonist used for management of GIT disturbance and it has anti-psychotic activities based on the administered dose. SUL undergoes P-glycoprotein efflux, which lead to poor bioavailability and erratic absorption. Therefore, the objective of this research was an attempt to enhance the oral bioavailability of SUL via formulation of fast disintegrating tablets (SUL-FDTs) with a rapid onset of action. A 32 full-factorial design was performed for optimization of SUL-FDTs using desirability function. The concentration of superdisintegrant ® (X1) and Prosolv (X2) were selected as independent formulation variables for the preparation and optimization of SUL-FDTs using direct compression technique. The prepared SUL-FDTs were investigated regarding their mechanical strength, disintegration time, drug release and in vivo pharmacokinetic analysis in rabbits.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • SCP Achei Memantine for Alzheimers Disease Oct 2018

    SCP Achei Memantine for Alzheimers Disease Oct 2018

    1 Somerset Healthcare Community Shared Care Protocol for the use of Acetylcholinesterase Inhibitors or Memantine in the Management of Alzheimer’s Disease This shared care protocol (SCP) sets out details for the sharing of care for patients prescribed any of the following drugs in the management of Disease – donepezil, rivastigmine, galantamine or memantine. It should be read in conjunction with the latest Summary of Products Characteristics (SPC) available for each drug at http://www.medicines.org.uk/emc/ As outlined in NHS England Guidance 2018 (07573), ‘Responsibility for Prescribing Between Primary, Secondary and Tertiary Care.’ When a consultant considers a patients’ condition is stable or predictable he/she may seek the agreement of the patients and their GP to “share” the patients’ care. This document provides information on drug treatment for the shared commitment between the consultant and GP concerned. GPs are invited to participate. If the GP is not confident to undertake these roles, then they are under no obligation to do so. In such an event, the total clinical responsibility for the patient for the diagnosed condition remains with the specialist. The doctor who prescribesShared the Care medication Protocol has the clinical responsibility for the drug and the consequences of its use. N.B.Atomoxetine If the GP decides for Attentionnot to participate Deficit in shared care for a particular patient, they must inform the relevant specialistHyperactivity in writing, Disorderwithin 2 weeks (ADHD) of receipt of a request to share care. Introduction This shared care guideline sets out details to support the transfer of responsibility for prescribing acetylcholinesterase inhibitors or memantine from secondary to primary care.
  • Pharmacy and Poisons Act 1979

    Pharmacy and Poisons Act 1979

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
  • Quality Issues in Caring for Older People

    Quality Issues in Caring for Older People

    Doctoral Thesis - Tesis Doctoral Quality issues in caring for older people: • Appropriateness of transition from long-term care facilities to acute hospital care • Potentially inappropriate medication: development of a European list Anna Renom Guiteras Prof. Gabriele Meyer Prof. Ramón Miralles Basseda Martin Luther University Halle-Wittenberg Universitat Autònoma de Barcelona Halle (Saale) & Barcelona, Catalonia University of Witten/Herdecke Spain Witten Germany Programa de doctorat en Medicina Departament de Medicina, Facultat de Medicina Universitat Autònoma de Barcelona Barcelona, 2015 13 Contents 15 1. Introduction • Research context • Background of the research topics • Pesetaio of the ailes 23 2. Summary and discussion of the results 31 3. Conclusions 37 4. References 47 5. Articles • Article 1: Renom-Guiteras A, Uhrenfeldt L, Meyer G, Mann E. Assessment tools for determining appropriateness of admission to acute care of persons transferred from long-term care facilities: a systematic review. BMC Geriatr. 2014;14:80 • Article 2: Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861-75 77 6. Annexes • Annex 1.1 (article 1) - Additional file 1: Studies dealing with assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 1.2 (article 1) - Additional file 2: Characteristics of the assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 2.1 (article 2) - Appendix 1: Complete EU(7)-PIM list • Annex 2.2 (article 2) - Appendix 2: Questionable Potentially Inappropriate Medications (Questionable PIM): results of the Delphi survey.
  • Metoclopramide: an Antiemetic in Chemotherapy Induced Nausea and Vomiting

    Metoclopramide: an Antiemetic in Chemotherapy Induced Nausea and Vomiting

    Central Journal of Drug Design and Research Bringing Excellence in Open Access Mini Review *Corresponding author Jørn Herrstedt, Department of Oncology, Odense University Hospital, DK-5000, Odense C, Denmark, Tel: Metoclopramide: An Antiemetic 45-6541-3634; Email: Submitted: 13 January 2017 Accepted: 16 March 2017 in Chemotherapy Induced Published: 17 March 2017 ISSN: 2379-089X Nausea and Vomiting Copyright © 2017 Herrstedt et al. 1 2 Signe Ladegaard Harder and Jørn Herrstedt * OPEN ACCESS 1Department of Oncology, Odense University Hospital, Denmark 2Department of Oncology, Odense University Hospital and the University of Southern Keywords Denmark, Denmark • Metoclopramide • Chemotherapy Abstract • Nausea • Vomiting Chemotherapy induced nausea and vomiting (CINV) are two of the most • Emesis feared adverse events experienced by cancer patients undergoing chemotherapy. Metoclopramide was derived from procainamide in the 1950s and one of the first drugs investigated in the prophylaxis of nausea and vomiting induced by chemotherapy. The breakthrough came in 1981 with the recognition that high-dose metoclopramide was effective and tolerable in the prevention of cisplatin-induced nausea and vomiting. A combination of high- dose metoclopramide and a corticosteroid was the standard antiemetic recommendation until the serotonin (5-HT)3-receptor antagonists, ondansetron, granisetron, tropisetron and dolasetron became available in the beginning of the 1990s. The development of these highly selective (5-HT)3-receptor antagonists with a superior effect and a preferable tolerability profile has limited the use of metoclopramide to be prescribed as a rescue antiemetic, when guideline recommended antiemetic therapy fails. ABBREVIATIONS The emetic risk of chemotherapy is divided in high emetic risk (risk of vomiting 0-24 hours after chemotherapy > 90%), CINV: Chemotherapy-Induced Nausea and Vomiting; moderate emetic risk (30-90%), low emetic risk (10-30%) and MCP: Metoclopramide; NK -Receptor Antagonist: Neurokinin 1 minimal emetic risk (< 10%).